uploads/2018/04/dna-163466.jpg

GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend

By

Updated

GlaxoSmithKline’s revenues

GlaxoSmithKline (GSK) reported revenues of ~7.2 billion pounds for 1Q18 on April 25, a ~2% decline from its ~7.3 billion pounds in 1Q17. This change includes 4% growth in revenues at constant exchange rates, offset by a 6% decrease in revenues due to the negative impact of foreign exchange. The company’s stock is listed on the London Stock Exchange, and the company reports its financial statements in pounds sterling. GlaxoSmithKline reported revenues of ~7.2 billion in 1Q18, a ~2% decline from its revenues of ~7.3 billion pounds in 1Q17. This change includes 4% growth in revenues at constant exchange rates, offset by a 6% decrease in revenues due to the negative impact of foreign exchange.

The above chart compares the quarterly revenues for GlaxoSmithKline since 1Q17.

Article continues below advertisement

Revenues for 1Q18

GlaxoSmithKline beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18, and it reported EPS of 24.60 pence on revenues of 7.22 billion pounds, compared to analysts’ estimate of 24.21 pence at revenues of 7.20 billion pounds.

GlaxoSmithKline has divided its product portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. In 1Q18, all these segments reported growth in operating revenues, which was more than offset by the negative impact of foreign exchange.

The Pharmaceuticals segment reported 2% growth in operating revenues to 4.0 billion pounds in 1Q18, offset by a -6% impact of foreign exchange. The growth in operating revenues was driven by strong sales of HIV products and immune-inflammation products, offset by lower sales of respiratory products and established pharmaceutical products.

The Vaccines segment reported 13% growth in operating revenues to 1.2 billion pounds in 1Q18, offset by a -6% impact of foreign exchange. The growth in operating revenues was driven by strong sales of shingles vaccines and established vaccines, offset by lower sales of meningitis and influenza vaccines.

The Consumer Healthcare segment reported 2% growth in operating revenues to ~2.0 billion pounds in 1Q18, offset by a -5% impact of foreign exchange. The growth in operating revenues was driven by strong sales of Oral Health products and Wellness products, offset by lower sales of Nutrition and Skin Health products.

Tthe First Trust Value Line Dividend ETF (FVD) invests 0.5% of its total investments in GlaxoSmithKline ADR (GSK), 0.5% in Novartis ADR (NVS), 0.5% in Merck & Co. (MRK), and 0.5% in Pfizer (PFE).

Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist